25 XP   0   0   10

INmune Bio Inc
Buy, Hold or Sell?

Let's analyse INmune Bio Inc together

PenkeI guess you are interested in INmune Bio Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of INmune Bio Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about INmune Bio Inc

I send you an email if I find something interesting about INmune Bio Inc.

Quick analysis of INmune Bio Inc (30 sec.)










What can you expect buying and holding a share of INmune Bio Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.12
Expected worth in 1 year
$0.90
How sure are you?
26.9%

+ What do you gain per year?

Total Gains per Share
$-1.22
Return On Investment
-12.0%

For what price can you sell your share?

Current Price per Share
$10.14
Expected price per share
$7.661 - $14.74
How sure are you?
50%

1. Valuation of INmune Bio Inc (5 min.)




Live pricePrice per Share (EOD)

$10.14

Intrinsic Value Per Share

$-11.40 - $-13.22

Total Value Per Share

$-9.28 - $-11.10

2. Growth of INmune Bio Inc (5 min.)




Is INmune Bio Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$38.1m$67.3m-$20.1m-42.7%

How much money is INmune Bio Inc making?

Current yearPrevious yearGrowGrow %
Making money-$7.5m-$7.1m-$368.5k-4.9%
Net Profit Margin-20,393.1%-16,106.6%--

How much money comes from the company's main activities?

3. Financial Health of INmune Bio Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#505 / 1009

Most Revenue
#661 / 1009

Most Profit
#506 / 1009

Most Efficient
#963 / 1009

What can you expect buying and holding a share of INmune Bio Inc? (5 min.)

Welcome investor! INmune Bio Inc's management wants to use your money to grow the business. In return you get a share of INmune Bio Inc.

What can you expect buying and holding a share of INmune Bio Inc?

First you should know what it really means to hold a share of INmune Bio Inc. And how you can make/lose money.

Speculation

The Price per Share of INmune Bio Inc is $10.14. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of INmune Bio Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in INmune Bio Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.12. Based on the TTM, the Book Value Change Per Share is $-0.30 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.28 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of INmune Bio Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.47-4.6%-0.42-4.1%-0.38-3.7%-0.30-2.9%-0.26-2.5%
Usd Book Value Change Per Share-0.37-3.6%-0.30-3.0%-0.28-2.8%0.060.6%0.080.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.37-3.6%-0.30-3.0%-0.28-2.8%0.060.6%0.080.8%
Usd Price Per Share11.26-8.39-7.45-9.39-7.23-
Price to Earnings Ratio-6.03--5.09--4.96--14.05--10.81-
Price-to-Total Gains Ratio-30.78--27.71--27.67--31.00--31.00-
Price to Book Ratio5.32-3.35-1.98-3.96-3.05-
Price-to-Total Gains Ratio-30.78--27.71--27.67--31.00--31.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.14
Number of shares98
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.300.06
Usd Total Gains Per Share-0.300.06
Gains per Quarter (98 shares)-29.865.87
Gains per Year (98 shares)-119.4423.49
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-119-12902313
20-239-24804736
30-358-36707059
40-478-48609482
50-597-6050117105
60-717-7240141128
70-836-8430164151
80-956-9620188174
90-1075-10810211197
100-1194-12000235220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.025.01.00.0%0.025.01.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%7.019.00.026.9%7.019.00.026.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.026.00.0%0.00.026.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%7.019.00.026.9%7.019.00.026.9%

Fundamentals of INmune Bio Inc

About INmune Bio Inc

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Fundamental data was last updated by Penke on 2024-04-11 11:52:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of INmune Bio Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit INmune Bio Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare INmune Bio Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -30,028.6% means that $-300.29 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of INmune Bio Inc:

  • The MRQ is -30,028.6%. The company is making a huge loss. -2
  • The TTM is -20,393.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-30,028.6%TTM-20,393.1%-9,635.4%
TTM-20,393.1%YOY-16,106.6%-4,286.5%
TTM-20,393.1%5Y-8,336,887.3%+8,316,494.2%
5Y-8,336,887.3%10Y-6,412,990.2%-1,923,897.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30,028.6%-200.1%-29,828.5%
TTM-20,393.1%-216.8%-20,176.3%
YOY-16,106.6%-288.3%-15,818.3%
5Y-8,336,887.3%-449.1%-8,336,438.2%
10Y-6,412,990.2%-605.5%-6,412,384.7%
1.1.2. Return on Assets

Shows how efficient INmune Bio Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare INmune Bio Inc to the Biotechnology industry mean.
  • -14.8% Return on Assets means that INmune Bio Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of INmune Bio Inc:

  • The MRQ is -14.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.8%TTM-11.7%-3.1%
TTM-11.7%YOY-8.2%-3.4%
TTM-11.7%5Y-9.2%-2.5%
5Y-9.2%10Y-9.8%+0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.8%-13.3%-1.5%
TTM-11.7%-12.8%+1.1%
YOY-8.2%-11.7%+3.5%
5Y-9.2%-13.9%+4.7%
10Y-9.8%-15.7%+5.9%
1.1.3. Return on Equity

Shows how efficient INmune Bio Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare INmune Bio Inc to the Biotechnology industry mean.
  • -22.0% Return on Equity means INmune Bio Inc generated $-0.22 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of INmune Bio Inc:

  • The MRQ is -22.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.0%TTM-16.5%-5.5%
TTM-16.5%YOY-10.7%-5.8%
TTM-16.5%5Y-11.2%-5.3%
5Y-11.2%10Y-11.4%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.0%-16.9%-5.1%
TTM-16.5%-16.1%-0.4%
YOY-10.7%-15.1%+4.4%
5Y-11.2%-19.3%+8.1%
10Y-11.4%-20.2%+8.8%

1.2. Operating Efficiency of INmune Bio Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient INmune Bio Inc is operating .

  • Measures how much profit INmune Bio Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare INmune Bio Inc to the Biotechnology industry mean.
  • An Operating Margin of 46,367.9% means the company generated $463.68  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of INmune Bio Inc:

  • The MRQ is 46,367.9%. The company is operating very efficient. +2
  • The TTM is -13,744.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ46,367.9%TTM-13,744.1%+60,112.0%
TTM-13,744.1%YOY-26,505.8%+12,761.7%
TTM-13,744.1%5Y-8,210,714.0%+8,196,969.9%
5Y-8,210,714.0%10Y-6,315,933.9%-1,894,780.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ46,367.9%-296.2%+46,664.1%
TTM-13,744.1%-232.5%-13,511.6%
YOY-26,505.8%-298.2%-26,207.6%
5Y-8,210,714.0%-492.1%-8,210,221.9%
10Y-6,315,933.9%-632.4%-6,315,301.5%
1.2.2. Operating Ratio

Measures how efficient INmune Bio Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 300.25 means that the operating costs are $300.25 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of INmune Bio Inc:

  • The MRQ is 300.250. The company is inefficient in keeping operating costs low. -1
  • The TTM is 202.493. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ300.250TTM202.493+97.757
TTM202.493YOY144.277+58.216
TTM202.4935Y82,101.091-81,898.598
5Y82,101.09110Y63,154.685+18,946.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ300.2503.231+297.019
TTM202.4933.310+199.183
YOY144.2773.890+140.387
5Y82,101.0915.739+82,095.352
10Y63,154.6857.876+63,146.809

1.3. Liquidity of INmune Bio Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if INmune Bio Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.16 means the company has $2.16 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of INmune Bio Inc:

  • The MRQ is 2.163. The company is able to pay all its short-term debts. +1
  • The TTM is 3.725. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.163TTM3.725-1.562
TTM3.725YOY17.588-13.863
TTM3.7255Y13.049-9.324
5Y13.04910Y11.317+1.733
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1633.890-1.727
TTM3.7254.173-0.448
YOY17.5885.344+12.244
5Y13.0496.126+6.923
10Y11.3176.448+4.869
1.3.2. Quick Ratio

Measures if INmune Bio Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare INmune Bio Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.07 means the company can pay off $2.07 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of INmune Bio Inc:

  • The MRQ is 2.074. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.535. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.074TTM3.535-1.461
TTM3.535YOY16.493-12.959
TTM3.5355Y12.561-9.027
5Y12.56110Y10.201+2.360
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0743.514-1.440
TTM3.5353.998-0.463
YOY16.4935.380+11.113
5Y12.5616.105+6.456
10Y10.2016.404+3.797

1.4. Solvency of INmune Bio Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of INmune Bio Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare INmune Bio Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.33 means that INmune Bio Inc assets are financed with 33.1% credit (debt) and the remaining percentage (100% - 33.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of INmune Bio Inc:

  • The MRQ is 0.331. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.286. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.331TTM0.286+0.045
TTM0.286YOY0.227+0.059
TTM0.2865Y0.153+0.132
5Y0.15310Y0.173-0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3310.339-0.008
TTM0.2860.336-0.050
YOY0.2270.271-0.044
5Y0.1530.366-0.213
10Y0.1730.389-0.216
1.4.2. Debt to Equity Ratio

Measures if INmune Bio Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare INmune Bio Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 49.5% means that company has $0.49 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of INmune Bio Inc:

  • The MRQ is 0.495. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.403. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.495TTM0.403+0.092
TTM0.403YOY0.295+0.108
TTM0.4035Y0.201+0.201
5Y0.20110Y0.159+0.043
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4950.388+0.107
TTM0.4030.402+0.001
YOY0.2950.335-0.040
5Y0.2010.426-0.225
10Y0.1590.461-0.302

2. Market Valuation of INmune Bio Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings INmune Bio Inc generates.

  • Above 15 is considered overpriced but always compare INmune Bio Inc to the Biotechnology industry mean.
  • A PE ratio of -6.03 means the investor is paying $-6.03 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of INmune Bio Inc:

  • The EOD is -5.434. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.034. Based on the earnings, the company is expensive. -2
  • The TTM is -5.085. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.434MRQ-6.034+0.600
MRQ-6.034TTM-5.085-0.948
TTM-5.085YOY-4.958-0.127
TTM-5.0855Y-14.047+8.961
5Y-14.04710Y-10.805-3.242
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.434-2.264-3.170
MRQ-6.034-2.629-3.405
TTM-5.085-2.680-2.405
YOY-4.958-4.145-0.813
5Y-14.047-6.257-7.790
10Y-10.805-6.254-4.551
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of INmune Bio Inc:

  • The EOD is -13.433. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -14.917. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.117. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.433MRQ-14.917+1.484
MRQ-14.917TTM-15.117+0.200
TTM-15.117YOY-6.490-8.627
TTM-15.1175Y-16.282+1.165
5Y-16.28210Y-12.525-3.757
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.433-2.973-10.460
MRQ-14.917-3.333-11.584
TTM-15.117-3.553-11.564
YOY-6.490-5.605-0.885
5Y-16.282-8.376-7.906
10Y-12.525-8.865-3.660
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of INmune Bio Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.32 means the investor is paying $5.32 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of INmune Bio Inc:

  • The EOD is 4.791. Based on the equity, the company is fair priced.
  • The MRQ is 5.321. Based on the equity, the company is overpriced. -1
  • The TTM is 3.346. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.791MRQ5.321-0.529
MRQ5.321TTM3.346+1.975
TTM3.346YOY1.985+1.361
TTM3.3465Y3.965-0.619
5Y3.96510Y3.050+0.915
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.7911.896+2.895
MRQ5.3212.115+3.206
TTM3.3462.093+1.253
YOY1.9852.884-0.899
5Y3.9653.542+0.423
10Y3.0503.916-0.866
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of INmune Bio Inc.

3.1. Institutions holding INmune Bio Inc

Institutions are holding 13.837% of the shares of INmune Bio Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc3.00740.0001541329-9251-1.6802
2023-12-31BlackRock Inc1.43290.00012579292510510.7828
2023-12-31Rhenman Partners Asset Management AB0.99050.200617828400
2023-12-31Geode Capital Management, LLC0.94470.000217004029371.7576
2023-12-31Janney Montgomery Scott LLC0.90870.006163559-93328-36.3304
2023-12-31Deutsche Bank AG0.61030.000610984800
2023-12-31Mccormack Advisors International0.54450.0145980126020.618
2023-12-31Quadrant Capital Group LLC0.33330.0586000000
2023-12-31Royal Bank of Canada0.32110.000257791-14892-20.489
2023-12-31State Street Corporation0.25040450631000.2224
2023-12-31Susquehanna International Group, LLP0.24350.0001438361199537.6716
2023-12-31UBS Group AG0.24010.00024321513653.2616
2023-12-31JANE STREET GROUP, LLC0.23960.000143134431340
2023-12-31Westside Investment Management, Inc.0.23260.1205418653250.7824
2023-12-31Citigroup Inc0.19940.000335900359000
2023-12-31Bank of New York Mellon Corp0.18560.0001334005091.5475
2023-12-31Laird Norton Tyee Trust Co0.1750.041931500315000
2023-12-31Qube Research & Technologies0.16350.000729437294370
2023-12-31Fermata Advisors, LLC0.16350.07929426-27276-48.1041
2023-12-31Northern Trust Corp0.13930.000125069479923.6754
Total 11.32590.52332038637+42961+2.1%

3.2. Funds holding INmune Bio Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.00510.000336145200
2023-12-31Rhenman Healthcare Equity L/S RC2 SEK0.9890.217317828400
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.92020.001916587400
2024-02-29Fidelity Extended Market Index0.36330.00265484-317-0.4818
2024-03-27Fidelity Nasdaq Composite ETF0.20980.00733782100
2024-02-29Fidelity Total Market Index0.17210.00043102000
2024-03-28iShares Micro-Cap ETF0.14410.03322597410534.2254
2023-09-30BlackRock Extended Mkt Composite0.14230.00122566000
2024-03-31BlackRock Extended Equity Market K0.12420.00182239480.0357
2024-02-29Fidelity Series Total Market Index0.08660.00031561200
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.07930.002614293479950.5477
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.07610.000413715-347737-96.2056
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.06370.002611479386950.841
2024-02-29Fidelity Nasdaq Composite Index0.06010.00081082900
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05460.0019984600
2023-12-31Northern Trust Extended Eq Market Idx0.05460.0019984600
2024-03-31BlackRock U.S. Equity Market F0.05150.00069288900.9785
2024-02-29Spartan Total Market Index Pool E0.0490.0003883800
2024-02-29DFA US Micro Cap I0.03150.0009567900
2024-02-29Spartan Extended Market Index Pool E0.02920.002452663176.4053
Total 5.70630.28011028654-337918-32.9%

3.3. Insider Transactions

Insiders are holding 34.918% of the shares of INmune Bio Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-10Scott JudaBUY70006.95
2023-07-12Timothy J SchroederSELL1000011.01

4. Summary

4.1. Key Performance Indicators

The key performance indicators of INmune Bio Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.366-0.305-17%-0.279-24%0.060-710%0.081-549%
Book Value Per Share--2.1162.619-19%3.737-43%2.651-20%2.228-5%
Current Ratio--2.1633.725-42%17.588-88%13.049-83%11.317-81%
Debt To Asset Ratio--0.3310.286+16%0.227+46%0.153+116%0.173+91%
Debt To Equity Ratio--0.4950.403+23%0.295+68%0.201+146%0.159+211%
Dividend Per Share----0%-0%-0%-0%
Eps---0.467-0.416-11%-0.379-19%-0.298-36%-0.257-45%
Free Cash Flow Per Share---0.189-0.166-12%-0.315+67%-0.215+14%-0.177-6%
Free Cash Flow To Equity Per Share---0.327-0.225-31%-0.305-7%100.255-100%82.233-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.962+4%
Intrinsic Value_10Y_max---13.218--------
Intrinsic Value_10Y_min---11.396--------
Intrinsic Value_1Y_max---1.193--------
Intrinsic Value_1Y_min---1.171--------
Intrinsic Value_3Y_max---3.684--------
Intrinsic Value_3Y_min---3.515--------
Intrinsic Value_5Y_max---6.296--------
Intrinsic Value_5Y_min---5.836--------
Market Cap182740038.000-11%202924342.000151247117.250+34%134261665.000+51%169268817.250+20%130206782.500+56%
Net Profit Margin---300.286-203.931-32%-161.066-46%-83368.873+27663%-64129.902+21256%
Operating Margin--463.679-137.441+130%-265.058+157%-82107.140+17808%-63159.339+13721%
Operating Ratio--300.250202.493+48%144.277+108%82101.091-100%63154.685-100%
Pb Ratio4.791-11%5.3213.346+59%1.985+168%3.965+34%3.050+74%
Pe Ratio-5.434+10%-6.034-5.085-16%-4.958-18%-14.047+133%-10.805+79%
Price Per Share10.140-11%11.2608.393+34%7.450+51%9.393+20%7.225+56%
Price To Free Cash Flow Ratio-13.433+10%-14.917-15.117+1%-6.490-56%-16.282+9%-12.525-16%
Price To Total Gains Ratio-27.717+10%-30.779-27.712-10%-27.670-10%-30.999+1%-30.999+1%
Quick Ratio--2.0743.535-41%16.493-87%12.561-83%10.201-80%
Return On Assets---0.148-0.117-21%-0.082-44%-0.092-38%-0.098-34%
Return On Equity---0.220-0.165-25%-0.107-52%-0.112-49%-0.114-48%
Total Gains Per Share---0.366-0.305-17%-0.279-24%0.060-710%0.081-549%
Usd Book Value--38139000.00047205250.000-19%67346250.000-43%47777608.250-20%40160829.923-5%
Usd Book Value Change Per Share---0.366-0.305-17%-0.279-24%0.060-710%0.081-549%
Usd Book Value Per Share--2.1162.619-19%3.737-43%2.651-20%2.228-5%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.467-0.416-11%-0.379-19%-0.298-36%-0.257-45%
Usd Free Cash Flow---3401000.000-2995000.000-12%-5671500.000+67%-3874915.100+14%-3074332.923-10%
Usd Free Cash Flow Per Share---0.189-0.166-12%-0.315+67%-0.215+14%-0.177-6%
Usd Free Cash Flow To Equity Per Share---0.327-0.225-31%-0.305-7%100.255-100%82.233-100%
Usd Market Cap182740038.000-11%202924342.000151247117.250+34%134261665.000+51%169268817.250+20%130206782.500+56%
Usd Price Per Share10.140-11%11.2608.393+34%7.450+51%9.393+20%7.225+56%
Usd Profit---8408000.000-7530250.000-10%-7161750.000-15%-5444273.600-35%-4682835.769-44%
Usd Revenue--28000.00038750.000-28%93500.000-70%3920446.000-99%3015727.692-99%
Usd Total Gains Per Share---0.366-0.305-17%-0.279-24%0.060-710%0.081-549%
 EOD+3 -5MRQTTM+5 -28YOY+9 -245Y+10 -2310Y+9 -25

4.2. Fundamental Score

Let's check the fundamental score of INmune Bio Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.434
Price to Book Ratio (EOD)Between0-14.791
Net Profit Margin (MRQ)Greater than0-300.286
Operating Margin (MRQ)Greater than0463.679
Quick Ratio (MRQ)Greater than12.074
Current Ratio (MRQ)Greater than12.163
Debt to Asset Ratio (MRQ)Less than10.331
Debt to Equity Ratio (MRQ)Less than10.495
Return on Equity (MRQ)Greater than0.15-0.220
Return on Assets (MRQ)Greater than0.05-0.148
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of INmune Bio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.589
Ma 20Greater thanMa 5010.330
Ma 50Greater thanMa 10011.504
Ma 100Greater thanMa 20011.371
OpenGreater thanClose10.370
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
EBIT  -6,799-6,047-12,84624-12,822-4,234-17,05630,03912,983
Depreciation and Amortization  1,1575,2666,423-126,4112,1178,528-29,890-21,362



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets57,001
Total Liabilities18,862
Total Stockholder Equity38,139
 As reported
Total Liabilities 18,862
Total Stockholder Equity+ 38,139
Total Assets = 57,001

Assets

Total Assets57,001
Total Current Assets39,942
Long-term Assets17,059
Total Current Assets
Cash And Cash Equivalents 35,848
Net Receivables 2,442
Other Current Assets 1,652
Total Current Assets  (as reported)39,942
Total Current Assets  (calculated)39,942
+/-0
Long-term Assets
Property Plant Equipment 414
Intangible Assets 16,514
Long-term Assets Other 131
Long-term Assets  (as reported)17,059
Long-term Assets  (calculated)17,059
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities18,465
Long-term Liabilities397
Total Stockholder Equity38,139
Total Current Liabilities
Short-term Debt 10,040
Short Long Term Debt 9,921
Accounts payable 7,936
Other Current Liabilities 8,425
Total Current Liabilities  (as reported)18,465
Total Current Liabilities  (calculated)36,322
+/- 17,857
Long-term Liabilities
Capital Lease Obligations 516
Long-term Liabilities  (as reported)397
Long-term Liabilities  (calculated)516
+/- 119
Total Stockholder Equity
Common Stock817
Retained Earnings -121,022
Accumulated Other Comprehensive Income -799
Other Stockholders Equity 159,143
Total Stockholder Equity (as reported)38,139
Total Stockholder Equity (calculated)38,139
+/-0
Other
Capital Stock817
Cash and Short Term Investments 35,848
Common Stock Shares Outstanding 17,951
Current Deferred Revenue489
Liabilities and Stockholders Equity 57,001
Net Debt -25,411
Net Invested Capital 48,060
Net Working Capital 21,477
Property Plant and Equipment Gross 414
Short Long Term Debt Total 10,437



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302016-12-31
> Total Assets 
452
0
18,413
18,830
18,230
17,678
17,363
23,645
27,530
25,396
24,470
23,678
23,048
42,816
40,656
65,874
60,700
107,672
99,945
94,353
87,809
83,800
81,795
73,979
69,720
62,698
57,001
57,00162,69869,72073,97981,79583,80087,80994,35399,945107,67260,70065,87440,65642,81623,04823,67824,47025,39627,53023,64517,36317,67818,23018,83018,4130452
   > Total Current Assets 
0
0
1,899
2,316
1,716
1,164
849
7,131
10,807
8,683
7,765
6,981
6,359
26,137
23,986
49,213
44,049
90,931
82,606
77,059
70,546
66,658
64,675
56,881
52,608
45,611
39,942
39,94245,61152,60856,88164,67566,65870,54677,05982,60690,93144,04949,21323,98626,1376,3596,9817,7658,68310,8077,1318491,1641,7162,3161,89900
       Cash And Cash Equivalents 
142
0
1,371
1,956
1,108
651
186
6,049
9,364
7,383
6,996
5,931
4,817
24,311
21,967
45,340
39,520
84,471
74,810
66,729
61,213
57,405
52,153
51,003
47,825
41,813
35,848
35,84841,81347,82551,00352,15357,40561,21366,72974,81084,47139,52045,34021,96724,3114,8175,9316,9967,3839,3646,0491866511,1081,9561,3710142
       Net Receivables 
0
0
328
228
311
354
648
806
998
1,060
645
784
1,200
1,609
1,799
2,344
3,119
5,146
5,504
5,648
5,060
4,531
8,461
2,210
2,046
2,263
2,442
2,4422,2632,0462,2108,4614,5315,0605,6485,5045,1463,1192,3441,7991,6091,2007846451,06099880664835431122832800
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5,504
0
0
0
34
35
30
0
0
00303534000-5,504000000000000000000
   > Long-term Assets 
0
0
16,514
0
0
16,514
16,514
16,514
16,723
16,713
16,706
16,697
16,689
16,679
16,670
16,661
16,651
16,741
17,339
17,294
17,263
17,142
17,120
17,098
17,112
17,087
17,059
17,05917,08717,11217,09817,12017,14217,26317,29417,33916,74116,65116,66116,67016,67916,68916,69716,70616,71316,72316,51416,51416,5140016,51400
       Property Plant Equipment 
0
0
0
0
0
0
0
0
209
199
192
183
175
165
156
147
137
128
726
681
650
529
507
485
468
444
414
41444446848550752965068172612813714715616517518319219920900000000
       Intangible Assets 
0
0
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,514
16,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51416,51400
       Other Assets 
0
0
16,514
0
16,514
0
0
0
0
0
0
0
0
0
156
0
0
99
99
99
99
99
99
99
130
0
0
00130999999999999990015600000000016,514016,51400
> Total Liabilities 
601
0
310
196
195
211
824
781
693
687
861
1,271
1,363
1,610
1,903
2,312
17,467
19,417
19,720
18,711
17,876
20,094
21,691
18,683
19,066
17,966
18,862
18,86217,96619,06618,68321,69120,09417,87618,71119,72019,41717,4672,3121,9031,6101,3631,2718616876937818242111951963100601
   > Total Current Liabilities 
601
0
310
196
195
211
824
781
516
516
700
1,117
1,217
1,474
1,776
2,196
2,989
4,810
4,359
3,226
2,285
6,895
10,918
10,283
13,055
14,356
18,465
18,46514,35613,05510,28310,9186,8952,2853,2264,3594,8102,9892,1961,7761,4741,2171,1177005165167818242111951963100601
       Short-term Debt 
0
0
0
0
0
0
0
-481
8
16
8
18
7
20
34
23
36
38
72
82
113
2,644
5,087
7,606
10,101
10,106
10,040
10,04010,10610,1017,6065,0872,644113827238362334207188168-4810000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,500
5,000
7,500
10,000
10,000
9,921
9,92110,00010,0007,5005,0002,500000000000000000000000
       Accounts payable 
221
0
310
196
158
211
824
481
508
337
692
696
625
1,200
1,552
1,582
2,370
4,231
3,813
2,560
1,696
3,473
5,215
2,086
2,394
3,754
7,936
7,9363,7542,3942,0865,2153,4731,6962,5603,8134,2312,3701,5821,5521,2006256966923375084818242111581963100221
       Other Current Liabilities 
30
0
0
0
0
0
0
481
508
499
8
799
1,210
1,454
191
591
583
541
4,143
584
476
778
616
0
2,954
4,250
8,425
8,4254,2502,95406167784765844,1435415835911911,4541,210799849950848100000030
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
177
172
160
154
145
136
126
116
14,478
14,607
15,361
15,485
15,591
13,199
10,773
8,400
6,011
3,610
397
3973,6106,0118,40010,77313,19915,59115,48515,36114,60714,47811612613614515416017217700000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,348
14,401
14,458
14,514
14,571
12,129
9,697
7,264
4,822
0
0
004,8227,2649,69712,12914,57114,51414,45814,40114,3480000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24
111
199
287
375
463
550
638
726
0
0
00726638550463375287199111240000000000000000
> Total Stockholder Equity
0
0
18,104
18,633
18,035
17,467
16,540
22,864
26,837
24,709
23,610
22,407
21,685
41,206
38,753
63,562
43,233
88,255
80,225
75,642
69,933
63,706
60,104
55,296
50,654
44,732
38,139
38,13944,73250,65455,29660,10463,70669,93375,64280,22588,25543,23363,56238,75341,20621,68522,40723,61024,70926,83722,86416,54017,46718,03518,63318,10400
   Retained Earnings -121,022-112,614-104,051-97,550-91,014-85,181-77,456-70,618-63,715-54,044-44,586-37,931-33,375-30,171-25,454-23,347-21,276-18,958-15,891-15,499-13,598-11,718-10,178-4,004-1,15800
   Accumulated Other Comprehensive Income 
0
0
32
0
0
9
7
6
-19
-55
-9
-29
10
-38
11
12
-50
-118
1
56
-701
-1,142
-699
-708
-712
-735
-799
-799-735-712-708-699-1,142-701561-118-501211-3810-29-9-55-19679003200
   Capital Surplus 
0
0
0
0
0
0
25,446
33,671
42,687
43,661
44,834
45,722
47,068
71,352
72,105
101,466
87,854
142,399
143,921
146,186
148,072
150,011
151,799
153,536
155,399
0
0
00155,399153,536151,799150,011148,072146,186143,921142,39987,854101,46672,10571,35247,06845,72244,83443,66142,68733,67125,446000000
   Treasury Stock000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue155
Cost of Revenue-0
Gross Profit155155
 
Operating Income (+$)
Gross Profit155
Operating Expense-29,896
Operating Income-29,741-29,741
 
Operating Expense (+$)
Research Development20,273
Selling General Administrative9,623
Selling And Marketing Expenses0
Operating Expense29,89629,896
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-29,741
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-30,008-29,474
EBIT - interestExpense = 0
-30,008
-30,008
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-30,008
Earnings Before Interest and Taxes (EBITDA)-29,741
 
After tax Income (+$)
Income Before Tax-30,008
Tax Provision-0
Net Income From Continuing Ops-27,433-30,008
Net Income-30,008
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses29,896
Total Other Income/Expenses Net-2670
 

Technical Analysis of INmune Bio Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of INmune Bio Inc. The general trend of INmune Bio Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine INmune Bio Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of INmune Bio Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 12.48 < 14.74.

The bearish price targets are: 8.35 > 7.93 > 7.661.

Tweet this
INmune Bio Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of INmune Bio Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

INmune Bio Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of INmune Bio Inc. The current macd is -0.57065773.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the INmune Bio Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for INmune Bio Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the INmune Bio Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
INmune Bio Inc Daily Moving Average Convergence/Divergence (MACD) ChartINmune Bio Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of INmune Bio Inc. The current adx is 17.51.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy INmune Bio Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
INmune Bio Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of INmune Bio Inc. The current sar is 8.3.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
INmune Bio Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of INmune Bio Inc. The current rsi is 47.59. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
INmune Bio Inc Daily Relative Strength Index (RSI) ChartINmune Bio Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of INmune Bio Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the INmune Bio Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
INmune Bio Inc Daily Stochastic Oscillator ChartINmune Bio Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of INmune Bio Inc. The current cci is -20.79812367.

INmune Bio Inc Daily Commodity Channel Index (CCI) ChartINmune Bio Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of INmune Bio Inc. The current cmo is 1.1927628.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
INmune Bio Inc Daily Chande Momentum Oscillator (CMO) ChartINmune Bio Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of INmune Bio Inc. The current willr is -38.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that INmune Bio Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
INmune Bio Inc Daily Williams %R ChartINmune Bio Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of INmune Bio Inc.

INmune Bio Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of INmune Bio Inc. The current atr is 0.8820309.

INmune Bio Inc Daily Average True Range (ATR) ChartINmune Bio Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of INmune Bio Inc. The current obv is -1,041,367.

INmune Bio Inc Daily On-Balance Volume (OBV) ChartINmune Bio Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of INmune Bio Inc. The current mfi is 71.65.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
INmune Bio Inc Daily Money Flow Index (MFI) ChartINmune Bio Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for INmune Bio Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

INmune Bio Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of INmune Bio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.589
Ma 20Greater thanMa 5010.330
Ma 50Greater thanMa 10011.504
Ma 100Greater thanMa 20011.371
OpenGreater thanClose10.370
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of INmune Bio Inc with someone you think should read this too:
  • Are you bullish or bearish on INmune Bio Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about INmune Bio Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about INmune Bio Inc

I send you an email if I find something interesting about INmune Bio Inc.


Comments

How you think about this?

Leave a comment

Stay informed about INmune Bio Inc.

Receive notifications about INmune Bio Inc in your mailbox!